BNN.DE StockTwits Mentions

Track BNN.DE's AI-powered predictions, market trends, and investment insights.

BNN.DE AI Prediction BNN.DE Sentiment BNN.DE Reddit

Mock Tradesimulated, no real money

You don't hold BNN.DE in your mock portfolio yet.

BNN.DE StockTwits Mentions

Track BNN.DE's AI-powered predictions, market trends, and investment insights.

BNN.DE AI Prediction BNN.DE Sentiment BNN.DE Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)+6.6%

Price (7d)0.7%

Volume vs avg0.3x

Volatility vs normal1.0x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 4K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€2.71 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

BNN.DE AI Stock Analysis

Financial Performance

bearish

The negative EPS of -0.49 and a PE ratio of -6.61 indicate that BRAIN Biotech AG is currently loss-making and not generating positive net income. This points to ongoing profitability challenges and a business model that has yet to translate into sustainable earnings for shareholders. Without evidence of improving margins or a clear path to profitability, the financial profile appears weak from an equity-investor standpoint.

Negative EPS (-0.49) confirms that the company is not profitable on a per-share basis, signaling operating or structural challenges.
A negative PE ratio (-6.61) reflects loss-making status and makes traditional valuation comparisons difficult, often associated with higher risk.
Absent signs of improving earnings or margin expansion, the current financial performance leans toward a speculative rather than fundamentals-driven investment thesis.

Stock Price & Technicals

bullish

The stock has risen 29.6% over the last month and is trading at €3.24, clearly above its 200-day moving average of €2.48, indicating a strong short- to medium-term uptrend. Trading above the 200-day moving average is typically interpreted as a bullish technical signal, suggesting positive momentum and improving investor sentiment. While the exact RSI is not provided, the sharp recent gain implies the stock may be approaching overbought territory, warranting caution on near-term entry points.

Current price (€3.24) is significantly above the 200-day moving average (€2.48), a classic sign of a bullish technical trend.
A 29.6% price increase in the last month indicates strong positive momentum and heightened investor interest.
Given the rapid appreciation, the RSI is likely elevated, which can signal short-term overbought conditions even within a broader uptrend.

Alternative Data Signals

neutral

Alternative data for BRAIN Biotech AG presents a mixed picture: modest LinkedIn follower growth suggests some incremental professional interest, while Twitter/X and YouTube audiences are slightly shrinking. Website traffic appears very low at an estimated 1,377 visitors per month, and job postings are flat at just one opening, implying limited current expansion activity. Overall, these signals do not yet point to strong commercial traction or brand momentum, but they also do not indicate a sharp deterioration.

LinkedIn followers stand at 10,011, up 1.2% over 90 days, hinting at gradual growth in professional awareness and networking reach.
Twitter/X (801 followers, down 0.1%) and YouTube (113 subscribers, down 0.9%) show slight declines, suggesting stagnant or weakening engagement on key public-facing channels.
Website traffic of roughly 1,377 visitors per month and only 1 job opening (0.0% MoM change) indicate limited scale and no clear signal of aggressive hiring or rapid commercial expansion.

Conclusion

neutral

BRAIN Biotech AG’s stock is exhibiting strong positive price momentum and a bullish technical setup, but this is not yet supported by underlying profitability, as evidenced by negative EPS and PE. Alternative data show only modest professional interest and limited operational scaling, with no clear surge in customer or market engagement. Taken together, the setup looks like a momentum-driven move in a fundamentally weak, early-stage or turnaround story, leading to an overall neutral stance with elevated risk.

Bullish technicals (price well above 200-day moving average and strong recent gains) contrast with loss-making fundamentals and negative earnings.
Alternative data and hiring trends are tepid, suggesting that the recent stock strength may be driven more by sentiment or speculation than by clear, broad-based business acceleration.

AI Score

Hold

Alternative7

Fundamental1

Technical8

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold BNN.DE in your mock portfolio yet.